The immunohistochemistry test detects the folate receptor 1 protein, which is over-expressed in most ovarian cancers.

These jobs will propel the province towards being a global leader in biomanufacturing and life sciences. MISSISSAUGA, ON, Nov ...

Roche has secured CE mark approval for its immunohistochemistry (IHC) companion diagnostic test, VENTANA FOLR1 (FOLR1-2.1) ...

Executive Vice-President of Diagnostics, Africa, at Roche Diagnostics, Dr. Allan Pamba ... to diagnostics and integrating self-monitoring into routine care, enabling us to control our health,” he said ...

Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, ...

Swiss drug major Roche Group (RHHBY) announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, ...

Kazmierczak also appreciates that flexibility. “Roche provides phenomenal work-life balance, with great benefits, making it ...

The global companion diagnostics for oncology market size was US$ 2.9 billion in 2021. The global companion diagnostics for oncology market is forecast to grow to US$ 9.1 billion by 2030 by ...

Offering a simpler alternative to PET scans and CSF analysis, blood-based biomarker tests could improve accessibility of ...

Alongside opening the new offices, Roche Diagnostics capabilities in China have been further recognised as it has been ...